Ensign Peak Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Ensign Peak Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,577	Closed	-$200K	–	2272
2022 Q3	$200K	Sell	7,577 -950	-11%	-$34.9K	﹤0.01%	1877
2022 Q2	$379K	Hold	8,527	–	–	﹤0.01%	1576
2022 Q1	$422K	Hold	8,527	–	–	﹤0.01%	1624
2021 Q4	$434K	Sell	8,527 -8,390	-50%	-$435K	﹤0.01%	1675
2021 Q3	$944K	Hold	16,917	–	–	﹤0.01%	1456
2021 Q2	$724K	Buy	16,917 +3,200	+23%	+$132K	﹤0.01%	1522
2021 Q1	$573K	Buy	13,717 +1,500	+12%	+$69.6K	﹤0.01%	1582
2020 Q4	$569K	Hold	12,217	–	–	﹤0.01%	1578
2020 Q3	$519K	Hold	12,217	–	–	﹤0.01%	1524
2020 Q2	$586K	Hold	12,217	–	–	﹤0.01%	1429
2020 Q1	$562K	Buy	12,217 +400	+3%	+$20.1K	﹤0.01%	1363
2019 Q4	$710K	Buy	+11,817	New	+$705K	﹤0.01%	1447

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Ensign Peak Advisors's EGRX Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 7,577 shares — an estimated $200K sold.

Ensign Peak Advisors first reported a position in EGRX in Q4 2019 and held it in 12 quarters. The position peaked at $944K in Q3 2021. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

Ensign Peak Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Ensign Peak Advisors sold 7,577 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $200K.
Ensign Peak Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2019 and held it in 12 quarters.
Ensign Peak Advisors's Eagle Pharmaceuticals, Inc. position peaked at $944K in Q3 2021.
152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.